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T
he anthracycline doxorubicin (DOXO) is a widely used 
chemotherapeutic that is particularly efficacious against 
the subset of breast cancers that overexpress the ErbB2 
(HER2) receptor.1 Limiting its clinical use, however, is a 
cumulative dose-related cardiotoxicity characterized by left 
ventricular dysfunction that can ultimately culminate in 
congestive heart failure.2 Oncologists now limit the dosage 
of DOXO, and thus DOXO-induced cardiomyopathy is no 
longer a widespread clinical problem. However, this dose 
limitation is potentially deleterious for patients with cancer 
for whom DOXO is the most effective therapy. Therefore, 
approaches to mitigate the cardiotoxic effects of DOXO to 
enable increased dosing to combat malignancies remain an 
unmet clinical need.
Editorial see p 98 
Clinical Perspective on p 161
Sawyer and others have described the potential of 
neuregulin-1β (NRG1B), a ligand of the ErbB receptor 
family, for therapeutic application against DOXO-induced 
cardiotoxicity.3–8 NRG1B binds ErbB3 and ErbB4, 
predominantly inducing heterotypic interactions with 
ErbB2, which has no known ligand.9 ErbB2 and ErbB4, 
but not ErbB3, are expressed in the postnatal heart and are 
both critical for cardiac development and cardiac function.3 
NRG1B, a key mediator of endothelial–cardiomyocyte cross 
talk,9–11 has been shown to protect ventricular myocytes from 
anthracycline-induced apoptosis.5–7 Systemic administration 
of the epidermal growth factor–like domain of NRG1B (NRG) 
Background—Doxorubicin (DOXO) is an effective anthracycline chemotherapeutic, but its use is limited by cumulative 
dose-dependent cardiotoxicity. Neuregulin-1β is an ErbB receptor family ligand that is effective against DOXO-induced 
cardiomyopathy in experimental models but is also proneoplastic. We previously showed that an engineered bivalent 
neuregulin-1β (NN) has reduced proneoplastic potential in comparison with the epidermal growth factor–like domain of 
neuregulin-1β (NRG), an effect mediated by receptor biasing toward ErbB3 homotypic interactions uncommonly formed 
by native neuregulin-1β. Here, we hypothesized that a newly formulated, covalent NN would be cardioprotective with 
reduced proneoplastic effects in comparison with NRG.
Methods and Results—NN was expressed as a maltose-binding protein fusion in Escherichia coli. As established previously, 
NN stimulated antineoplastic or cytostatic signaling and phenotype in cancer cells, whereas NRG stimulated proneoplastic 
signaling and phenotype. In neonatal rat cardiomyocytes, NN and NRG induced similar downstream signaling. NN, 
like NRG, attenuated the double-stranded DNA breaks associated with DOXO exposure in neonatal rat cardiomyocytes 
and human cardiomyocytes derived from induced pluripotent stem cells. NN treatment significantly attenuated DOXO-
induced decrease in fractional shortening as measured by blinded echocardiography in mice in a chronic cardiomyopathy 
model (57.7±0.6% versus 50.9±2.6%, P=0.004), whereas native NRG had no significant effect (49.4±3.7% versus 
50.9±2.6%, P=0.813).
Conclusions—NN is a cardioprotective agent that promotes cardiomyocyte survival and improves cardiac function in 
DOXO-induced cardiotoxicity. Given the reduced proneoplastic potential of NN versus NRG, NN has translational 
potential for cardioprotection in patients with cancer receiving anthracyclines.   (Circulation. 2013;128:152-161.)
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leads to improved survival in animal models of ischemic, 
viral, and dilated cardiomyopathy6 and has demonstrated 
cardioprotective efficacy in clinical trials.12
However, despite its efficacy, NRG is not clinically relevant 
as a therapeutic for DOXO-induced cardiomyopathy because 
of its well-established role in proneoplastic signaling.13–16 We 
have previously designed an engineered bivalent neuregulin-
1β (NN) that demonstrates reduced proneoplastic potential in 
comparison with NRG.17 Whereas NRG is widely reported to 
participate in malignant signaling pathways via the induction 
of ErbB2/3 heterotypic interactions,13–16 NN biases signal-
ing away from these and toward ErbB3 homotypic interac-
tions in high ErbB3- and low ErbB4-expressing cancer cells.17 
Because ErbB3 is a very weak18 or inactive19 kinase, ErbB3 
homotypic interactions can result in a cytostatic or antineo-
plastic phenotype.17
If NN retains similar cardioprotective properties in com-
parison with NRG without the proneoplastic properties 
of NRG, then NN could represent a more translationally 
relevant therapy for DOXO-induced cardiomyopathy. We 
hypothesized that NN would promote cardioprotection in a 
manner similar to NRG, provided that NN-induced biasing to 
exclude ErbB2 participation in cardiomyocyte signaling was 
not extreme. Although the role of ErbB2 in chemotherapy-
related cardiotoxicity remains unclear, substantial inhibition 
of ErbB2 signaling may impair cardiac function, as observed 
in patients receiving concurrent treatment with anthracy-
clines and the ErbB2 antibody trastuzumab.2,20 We tested 
the stated hypothesis in vitro in rat and human cardiomyo-
cytes and in vivo in randomized and blinded mouse models 
of acute and chronic DOXO-induced cardiomyopathy. Our 
results indicate that NN induces antineoplastic or cytostatic 
responses in cancer cells that are stimulated toward known 
malignant signaling pathways and phenotypes by NRG, 
endowing NN with a reduced proneoplastic profile in com-
parison with NRG, and that NN is cardioprotective, working 
through similar mechanisms as NRG, and holds promise as a 
novel therapeutic for patients with cancer who are receiving 
anthracyclines.
Methods
Protein Design and Purification
The amino acid sequence for NN comprises 2 NRG domains sepa-
rated by a hydrophilic, protease-resistant spacer (Figure 1A). The full 





VMASFYKHLGIEFMEAE. Additional information is available in 
the Online-only Data Supplement.
Immunoblot and proteomic array analyses, cell culture procedures, 
and in vitro functional assays are described in the Online-only Data 
Supplement. Molecules used for stimulation included DOXO (doxo-
rubicin hydrochloride, Sigma-Aldrich, solubilized in sterile saline), 
NRG (epidermal growth factor–like domain, Peprotech), or NN. In 
general, NN was used at one-half the molar dose of NRG because NN 
contains 2 NRG domains; therefore, this dosing scheme should result 
in approximately equivalent doses.
In Vivo Studies
Two different randomized and blinded mouse models of DOXO-
induced cardiomyopathy, acute and chronic, were used. For the acute 
model, 8- to 12-week-old male C57BL/6 mice (total of 33, Charles 
River) were administered a single DOXO injection (20 mg/kg IP; 
Sigma-Aldrich). Selections of DOXO dose and route of administra-
tion were based on previous studies.7,21 NRG (100 μg/kg IP) or NN 
(100 μg/kg IP) was administered daily starting 3 days before and for 4 
days after DOXO administration. The timing and dosage of treatment 
injections were based on a previous study.7 Controls were treated 
with vehicle (0.2% bovine serum albumin in phosphate-buffered   
saline) only. Baseline echocardiography was performed on all ani-
mals 2 days before initial treatment injection, and animals were 
randomly assigned into groups based on fractional shortening (FS) 
values. Blinded echocardiography was performed after final treatment 
injection. Mice were anesthetized with pentobarbital (30–70 mg/kg).   
The left ventricle (LV) was imaged in the short-axis view at the 
midpapillary muscle, and 2-dimensional measurements of LV end-
diastolic diameter and LV end-systolic diameter were recorded. FS 
Figure 1.  Design of covalently linked bivalent neuregulin-1β (NN) and validation of its reduced proneoplastic potential in comparison with 
neuregulin-1β (NRG). A, NN was produced via covalent linkage of 2 NRG domains separated by a flexible, protease-resistant spacer. 
Purity was indicated by Coomassie-stained gel. B, Schematic of expected differential ErbB receptor complexation induced by NRG 
in comparison with NN in doxorubicin-sensitive breast cancer cells expressing ErbB2 and ErbB3. NRG is predicted to predominantly 
promote ErbB2/3 heterotypic interactions, whereas NN is predicted to induce increased ErbB3 homotypic interactions. C, Immunoblot 
analysis of ErbB2, ErbB3, Akt, and ERK1/2 phosphorylation in lysates from doxorubicin-sensitive human mammary ductal carcinoma 
cell line MDA-MB-175VII stimulated for 15 minutes by NRG or NN. GAPDH expression was measured as a loading control. Data are 
representative of 3 independent experiments. D, Cell number was assessed by measurement of DNA content via fluorescence (CyQUANT 
assay, ex=485 nm; em=530 nm) after stimulation of MDA-MB-175VII cells by control media (indicated by dashed line) or the indicated 
doses of NRG (left of slash) or NN (right of slash; n=6). Probability values were calculated by using a Wilcoxon rank-sum test. em 
indicates emission; ex, excitation; and RFU, relative fluorescence units.
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was then calculated (FS=[100×(LV end-diastolic diameter−LV end-
systolic diameter)/LV end-diastolic diameter]). Heart rates were 
determined by using M-mode images. Animals were euthanized fol-
lowing the final echocardiogram, and their hearts were excised and 
flash frozen before thawing and homogenization in lysis buffer for 
immunoblot analysis.
For the chronic model, 8- to 12-week-old female C57BL/6 mice 
(total of 44, Charles River) were administered serial DOXO injec-
tions (4 mg/kg IP; Sigma-Aldrich). Mice were injected once weekly 
for 5 consecutive weeks at the initiation of the study (weeks 0–4) 
and then again for 5 weeks beginning 16 weeks after the initial injec-
tion (weeks 16–20). Selection of DOXO dose and route of admin-
istration was based on a previous study.22 NRG (50 μg/kg IP) or 
NN (50 μg/kg IP) was administered daily for 1 week starting on 
the day of the first DOXO injection (week 0) and again daily for 1 
week during week 16. Vehicle-only treated animals were used as 
controls (0.2% bovine serum albumin in phosphate-buffered saline). 
Animals were randomly assigned as in the acute model. Blinded 
echocardiography was performed 6, 12, 22, and 24 weeks after the 
initial DOXO injection. Anesthesia and analysis were identical to 
those used in the acute model. Animals were euthanized following 
the final echocardiogram, and their hearts were excised and fixed 
in 4% paraformaldehyde overnight before dehydration, rehydration, 
and fixation in paraffin by standard methods. Five-micrometer sec-
tions were cut and stained with hematoxylin and eosin or Masson 
trichrome. All animal protocols were approved by the Harvard 
Institutional Animal Care and Use Committee and performed in an 
Association for Assessment and Accreditation of Laboratory Animal 
Care–certified facility.
Statistical Analysis
All data are shown as mean±standard error of the mean unless stated. 
Statistical significance was calculated by using nonparametric analy-
ses as indicated in the figure legends. Additional information is avail-
able in the Online-only Data Supplement.
Results
Design of Covalently Linked NN and Validation of 
Its Reduced Proneoplastic Potential in Comparison 
With NRG
We previously reported the development of bivalent ligands 
consisting of a noncovalent linkage of 2 monomeric receptor-
binding domains separated by a flexible, protease-resistant 
spacer and a high-affinity coiled-coil domain.17 To reduce the 
possibility for dissociation of ligands and thereby promoting 
the potential for clinical translation, a new covalently linked 
NN was engineered without a coiled-coil domain and with a 
corresponding increase in the length of the spacer (Figure 1A). 
Purity of the final product was verified by observation of a 
single band on a Coomassie-stained gel (Figure 1A).
Binding of NRG1B to ErbB3 and the subsequent forma-
tion of ErbB2/3 heterotypic interactions are associated with 
proneoplastic signaling in a wide range of cancers, including 
DOXO-sensitive breast cancers.14,16,23 We previously demon-
strated that NN promotes sequestration of ErbB3 into weak/
nonsignaling homotypic interactions, resulting in a cytostatic 
or antineoplastic phenotype17 (summarized schematically in 
Figure 1B). Here, we used the DOXO-sensitive, human mam-
mary ductal carcinoma cell line MDA-MB-175VII,24 which 
is stimulated by a neuregulin-1 autocrine loop whereby 
ErbB2 and ErbB3 are phosphorylated,25,26 to assess whether 
NN would exhibit reduced proneoplastic characteristics 
in comparison with native NRG. When stimulated for 15 
minutes with NRG, MDA-MB-175VII cells exhibited dose-
dependent phosphorylation of ErbB2 and ErbB3, as expected 
(Figure 1C). Stimulation with NN for 15 minutes, on the 
other hand, resulted in levels of phospho-ErbB2 and phospho-
ErbB3 that were lower than or similar to control levels, even 
at the highest tested doses of NN (Figure 1C). Furthermore, 
phosphorylation of downstream effectors Akt and ERK1/2, 
known mediators of proliferation, migration, and survival in 
cancer cells, was also modestly increased on stimulation by 
NRG but unchanged or decreased by stimulation with NN 
in comparison with control levels (Figure 1C). Additionally, 
NRG stimulation promoted maintenance or growth of MDA-
MB-175VII, whereas stimulation with an equivalent dosage 
of NN resulted in reduced cell viability in comparison with 
native NRG at dosages ≥50 nmol/L (Figure 1D). Thus, these 
data confirm the bioactivity of NN and reinforce its reduced 
proneoplastic potential in comparison with NRG in DOXO-
sensitive breast cancer cells.17
NN Stimulates ErbB Receptor Phosphorylation on 
Cardiomyocytes
Given the well-established roles for NRG in cardioprotec-
tion6,11,27–30 and as a potential therapy for DOXO-induced 
cardiomyopathy,3–8 we wanted to test whether NN, with its 
reduced proneoplastic potential in comparison with NRG, 
stimulated cardioprotective signaling in a manner similar to 
NRG. Postnatal cardiomyocytes express ErbB2 and ErbB4, 
but not ErbB39. ErbB4, unlike ErbB3, has a fully active kinase 
domain and can participate in signaling when complexed with 
either ErbB2 or ErbB49. NRG stimulation of cardiomyocytes 
results predominantly in the formation of ErbB2/4 heterotypic 
interactions,9 initiating downstream signaling (Figure 2A). 
We predicted that NN stimulation would induce biasing away 
from ErbB2/4 interactions toward ErbB4 homotypic interac-
tions, which would result in active downstream signaling that 
may or may not differ from that induced by ErbB2/4 interac-
tions (Figure 2A).
To assess the effect of NN on ErbB receptor phosphorylation 
on cardiomyocytes, neonatal rat cardiomyocytes (NRCMs) 
were stimulated for 15 minutes with either 10 nmol/L NRG 
or NN and lysates were analyzed by using phosphoreceptor 
tyrosine kinase arrays that enabled simultaneous evaluation 
of phosphorylation of all ErbB receptors. Stimulation with 
NN resulted in apparent increased ErbB4 phosphorylation 
and decreased ErbB2 phosphorylation in comparison with 
NRG, although ErbB2 phosphorylation still occurred with NN 
stimulation (Figure 2B). Thus, we established that, although 
NN stimulation results in ErbB receptor phosphorylation on 
cardiomyocytes consistent with the generation of increased 
ErbB4 homotypic interactions in comparison with stimulation 
with NRG, inhibition of ErbB2 phosphorylation is not 
extreme.
NN Induces Intracellular Signaling Similar to 
NRG and Phosphorylates Known Mediators of 
Cardioprotection
To assess whether ErbB receptor phosphorylation on 
cardiomyocytes associated with NN induced different 
downstream signaling in comparison with NRG, NRCM 
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lysates prepared by using the same conditions as described 
for Figure 2 were analyzed with intracellular phosphokinase 
arrays (Figure 3). Array analysis revealed substantial 
phosphorylation of Akt (S473) and ERK1/2, known mediators 
of cardioprotective effects,5,7,27 at similar levels for both NRG 
and NN stimulation (Figure 3A). Overall, no significant 
difference between NRG-treated cells and NN-treated cells 
was observed (Figure 3B). The same analysis was performed 
on lysates made 24 hours following stimulation by proteins 
or control media in the presence of 1 μmol/L DOXO. A 
distinction between the signaling profiles of NRCM stimulated 
with control media with DOXO (DOXO) and without DOXO 
(Control) was evident (Figure 3C and 3D). NRCMs stimulated 
with DOXO and NRG (DOXO+NRG) or DOXO and NN 
Figure 2.  Bivalent neuregulin-1β (NN) stimulates ErbB receptor phosphorylation on cardiomyocytes. A, Schematic of expected 
differential ErbB receptor complexation induced by neuregulin-1β (NRG) in comparison with NN on cardiomyocytes. NRG is predicted 
to predominantly promote formation of ErbB2/4 heterotypic interactions, whereas NN is predicted to induce increased ErbB4 homotypic 
interactions. B, Phospho-receptor tyrosine kinase array analysis of neonatal rat cardiomyocytes stimulated for 15 minutes by 10 nmol/L 
NRG or NN or serum-free media (Vehicle). Data are representative of 3 independent experiments. Legend indicates relative locations of 
positive control (+), negative control (−), phospho-ErbB2 (pErbB2), and phospho-ErbB4 (pErbB4) spots on array membrane.
Figure 3.  Bivalent neuregulin-1β (NN) 
induces intracellular signaling similar 
to NRG and phosphorylates, known 
mediators of cardioprotection. A, 
Expression data from phosphokinase 
array of neonatal rat cardiomyocytes 
(NRCMs) stimulated for 15 minutes 
by 50 nmol/L NRG or 25 nmol/L 
NN, Vehicle=serum-free media 
(n=3). B, Pathway analysis of data 
from A demonstrates similar protein 
phosphorylation patterns induced by 
NN and NRG. Data were thresholded 
to y axis=0.20 and displayed in order 
of relative expression in Vehicle group 
from low to high as indicated. C, 
Expression data from phospho-kinase 
array of NRCMs stimulated for 24 
hours by 50 nmol/L NRG or 25 nmol/L 
NN concurrently exposed to 1 μmol/L 
doxorubicin (DOXO), Vehicle=serum-free 
media (n=3). D, Pathway analysis of data 
from C demonstrates differential protein 
phosphorylation stimulated by DOXO in 
comparison with Vehicle. NN+DOXO and 
NRG+DOXO induced similar patterns 
that indicate significant regulation of 
numerous factors from their DOXO-
induced state toward the Vehicle state, 
indicative of cardioprotective signaling. 
Data were thresholded to y axis=0.75 and 
displayed in order of relative expression 
in the Vehicle group from low to high as 
indicated.
 at Harvard University on January 16, 2014 http://circ.ahajournals.org/ Downloaded from 156  Circulation  July 9, 2013
(DOXO+NN) had profiles that were generally more similar 
to Control, indicative of cardioprotective signaling, and that 
did not vary from each other in a statistically significant way 
(Figure 3C and 3D). Additional analyses of Akt and ERK1/2 
phosphorylation at different doses and time points revealed 
no significant differences between NRG- and NN-induced 
effects. Overall, these data support the conclusions that 
NN is capable of inducing canonical cardioprotective 
signaling in cardiomyocytes and that downstream signaling 
induced by NN is similar to that induced by NRG in vitro in 
cardiomyocytes.
NN Is Cardioprotective From DOXO In Vitro
Because stimulation with NRG or NN resulted in similar 
downstream signaling profiles, we hypothesized that NN 
would retain similar cardioprotective qualities to NRG in the 
setting of DOXO-induced toxicity. To test this, we assessed 
phenotype and signaling in response to DOXO exposure. 
Stimulation with 100 nmol/L NRG in the presence of 1 
μmol/L DOXO resulted in a significant increase in NRCM 
viability in comparison with DOXO-only treated cells, as 
expected (Figure 4A, P=0.013). Surprisingly, stimulation with 
50 nmol/L NN resulted in significantly greater preservation 
of NRCM viability than an approximately equivalent dos-
age of 100 nmol/L NRG (Figure 4A, P=0.038). Additionally, 
stimulation with 25 nmol/L NN significantly reduced NRCM 
apoptosis associated with DOXO and did so more effectively 
than stimulation with 50 nmol/L NRG (Figure 4B, P=0.002). 
Taken together, these data indicate that NN is cardioprotective 
from DOXO in vitro with comparable or enhanced potency in 
comparison with NRG.
One validated mechanism for the cardiotoxicity of DOXO 
is the generation of double-stranded DNA breaks, ultimately 
leading to cell death.31 Phosphorylation of the histone H2A.X, 
which yields γ-H2A.X, occurs in response to double-stranded 
DNA breaks and is a very early indicator of DNA damage.32 
Exposure of NRCM to 1 μmol/L DOXO and of human induced 
pluripotent stem cell–derived cardiomyocytes to 10 μmol/L 
DOXO resulted in increased γ-H2A.X signal (Figure 4C and 
4D). The increase in γ-H2A.X was similarly attenuated when 
stimulated with approximately equivalent concentrations of 
NRG (100 nmol/L) or NN (50 nmol/L) (Figure 4C and 4D). 
Thus, the cardioprotective effect of both NRG and NN may 
be explained by an attenuation of the double-stranded DNA 
breaks induced by DOXO.
NN Does Not Interfere With DOXO Activity on 
Anthracycline-Sensitive Cancer Cells
One possibility for the apparent effects of NN in 
counteracting DOXO-induced cardiomyocyte toxicity is 
nonspecific interference with DOXO by NN. To examine 
whether NN interfered with the cytotoxic action of DOXO, 
DOXO-sensitive mammary adenocarcinoma line SK-BR-3 
cells and HeLa cells were concurrently exposed to increasing 
doses of DOXO and a static dose of either 50 nmol/L NRG 
or 25 nmol/L NN. NN did not interfere with the cytotoxic 
action of DOXO at the assessed doses, indicating that the 
protective effects of NN on cardiomyocytes were not the 
result of the inactivation of DOXO (Figure 5A and 5B). 
Additionally, γ-H2A.X expression was unchanged in HeLa 
cells concurrently exposed to DOXO and NRG or NN 
(Figure 5C), further supporting the conclusion that NN 
does not interfere with DOXO activity and, thus, that any 
effects observed in cardiomyocytes are likely the result of 
stimulation of ErbB receptors and not of nonspecific DOXO 
inhibition.
Figure 4.  Bivalent neuregulin-1β (NN) has similar cardioprotective qualities to neuregulin-1β (NRG) in vitro. A, Neonatal rat 
cardiomyocytes (NRCMs) were exposed to 1 μmol/L doxorubicin (DOXO) and were stimulated with the indicated concentrations of 
NRG or NN in serum-free conditions for 24 hours. The control condition was NRCM in serum-free media (Vehicle). Cell viability was 
quantified via fluorescence (CyQUANT assay, ex=485 nm, em=530 nm; n=8). B, Presence of cleaved caspase-3/7 was assessed in 
NRCMs after exposure to 1 μmol/L DOXO and stimulation with NRG or NN for 24 hours via fluorescence (SensoLyte assay, ex=354 nm, 
em=442 nm; n=8). The control condition was NRCM in serum-free media (Vehicle). For A and B, probability values were determined 
by using a Wilcoxon rank-sum test with a Bonferroni correction after an initial Kruskal-Wallis test to determine statistical significance; 
data are representative of at least 2 independent experiments. RFU indicates relative fluorescence units. C, Immunoblot analysis of 
γ-H2A.X in NRCM stimulated with NRG (100 nmol/L) or NN (50 nmol/L) concurrently exposed to 1 μmol/L DOXO for 24 hours. NRCMs 
were incubated with treatments for 24 hours before DOXO addition (48 hours total treatment time). D, Immunoblot analysis of γ-H2A.X 
in human induced pluripotent stem cell–derived cardiomyocytes (iPSC-CM) stimulated with NRG (100 nmol/L) or NN (50 nmol/L) 
concurrently exposed to 10 μmol/L DOXO for 24 hours. iPSC-CM were incubated with treatments for 24 hours before DOXO addition 
(48 hours total treatment time). For C and D, GAPDH expression was assessed as a protein-loading control, data are representative of 3 
independent experiments, and the control condition was NRCM in serum-free media (Vehicle). em indicates emission; and ex, excitation.
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NN Confers Functional Protection From DOXO 
Toxicity In Vivo
To assess the efficacy of NN in vivo, we performed a pilot 
study applying a previously described model of acute 
DOXO-induced cardiomyopathy.7,21 We observed a trend, 
indicative of impaired left ventricular function, toward 
a decrease in FS, as detected by blinded echocardiogra-
phy, of mice treated with DOXO only (DOXO) in com-
parison with animals that did not receive DOXO (Vehicle) 
(Figure 6A, 59.4±1.0% versus 54.5±1.6%, P=0.026). 
Animals treated with NN displayed a trend toward attenu-
ation of the decrease in FS associated with DOXO expo-
sure (Figure 6A, 59.4±1.4% versus 54.5±1.6%, P=0.053). 
FS was not affected by treatment with NRG or NN alone. 
Additionally, the analysis of cross-sectional heart lysates 
from NN-treated study animals exhibited a decrease in 
γ-H2A.X expression in comparison with DOXO-treated 
animals (Figure 6B), suggesting that the beneficial effect 
of NN in DOXO-exposed animals could at least be par-
tially attributable to reduced double-stranded DNA breaks 
in the heart.
The efficacy of NN as a cardioprotective agent in vivo was 
further assessed by using a randomized and blinded mouse 
model of chronic DOXO-induced toxicity. In comparison 
with the acute model, this model is more representative of the 
clinical administration profile of DOXO. A significant decrease 
in FS of DOXO-treated mice (DOXO) in comparison with 
vehicle control (Vehicle) was observed at 24 weeks following 
the initial DOXO injection (Table and Figure 6C; 58.0±1.2% 
versus 50.9±2.6%, P=0.011). A significant increase in end-
systolic diameter and significantly lower body weight were 
also associated with DOXO treatment at 24 weeks (Table). 
Indicative of cardioprotection, animals treated with NN had a 
significant attenuation of the decrease in FS associated with 
DOXO exposure at 24 weeks (Table and Figure 6C; 57.7±0.6% 
versus 50.9±2.6%, P=0.004). In this model, NRG treatment 
had no effect on FS (49.4±3.7% versus 50.9±2.6%, P=0.813), 
and NN treatment led to a significantly higher FS than NRG 
(57.7±0.6% versus 49.4±3.7%, P=0.001). NN-treated mice 
also exhibited, in comparison with mice given DOXO only 
(DOXO), a trend toward increased posterior wall thickness 
and significantly decreased end-systolic diameter at 24 weeks 
(Table), similar to the Vehicle group values and indicative of 
a protective effect of NN on the heart. Histological analysis 
of tissue from study animals revealed pockets of necrotic 
tissue and fibrosis in DOXO-only animals, with these being 
less prevalent in NRG- and NN-treated animals (Figure I in 
the online-only Data Supplement). Additionally, all animals 
treated with DOXO showed similar weight loss in comparison 
with the Vehicle control group (Table), and thus the systemic 
effects of DOXO were not inhibited by NN even though 
cardiac function was improved, further evidence that NN is 
not an inhibitor of DOXO activity but rather a counteracting 
factor that works through a different mechanism, namely, 
ErbB receptor stimulation. This was further confirmed by 
detection of ErbB2 and ErbB4 phosphorylation in mouse 
hearts following injection of NN or NRG (Figure II in the 
online-only Data Supplement). Overall, these data support 
the conclusion that NN is cardioprotective from DOXO.
Discussion
NRG1B is a promising cardiovascular therapeutic, 
but has limited relevance for cardioprotection against   
anthracycline-induced cardiotoxicity because of its proneo-
plastic potential. We previously reported the development 
Figure 5.  Bivalent neuregulin-1β (NN) does not interfere with 
doxorubicin (DOXO) activity on anthracycline-sensitive cancer 
cells. A, Mammary adenocarcinoma line SK-BR-3 cells were 
concurrently exposed to DOXO at the indicated concentrations 
and stimulated with 50 nmol/L neuregulin-1β (NRG) or 25 nmol/L 
NN. Cell viability relative to control (serum-free media; 100%) 
was quantified via fluorescence (CyQUANT assay, ex=485 nm, 
em=530nm; n=5, data are representative of 3 independent 
experiments). IC50 values were calculated based on the best-
fit line generated with GraphPad Prism software. B, Identical 
experimental conditions were used with HeLa cells. C, HeLa 
cells were exposed to serum-free media (Vehicle) with or without 
1 μmol/L DOXO for 24 hours with concurrent stimulation by 50 
nmol/L NRG or 25 nmol/L NN as indicated, and immunoblot 
analysis of γ-H2A.X was performed on lysates. GAPDH 
expression was assessed as a protein-loading control. Data 
are representative of 3 independent experiments. em indicates 
emission; and ex, excitation.
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of NN, an engineered bivalent protein that can induce cyto-
static and antineoplastic phenotypes in numerous cancer 
cell lines, including DOXO-sensitive breast cancer cells.17 
Here, we show that a newly formulated NN retains these 
qualities and is also cardioprotective. Thus, NN may atten-
uate anthracycline-mediated cardiovascular toxicity, with-
out simultaneously promoting cancer growth, supporting 
its potential as a therapeutic adjunct to anthracyclines in 
patients with cancer.
These data are timely given the recent report of efficacy 
of NRG as a cardiovascular therapeutic in clinical trials,12 
and the initiation of clinical trials with another NRG1B 
molecule, Glial Growth Factor 2 (GGF2), as well.30 The 
differences between NRG and GGF2 may help to explain 
the apparent superior cardioprotection induced by NN 
in comparison with NRG despite the similarities in their   
cardiomyocyte-signaling profiles. In comparison with NRG, 
GGF2 is a larger protein that contains an immunoglobulin-
like domain. This immunoglobulin-like domain may enhance 
the duration of effects of GGF2 versus NRG via interactions 
with matrix molecules that prolong tissue residence times.30 
Thus, the differences in potency between NN and NRG in 
our experiments may be the result of increased cell or tis-
sue interactions with NN because of its larger size or dif-
ferences in receptor trafficking attributable to the tethered 
nature of the NRG domains on NN. It also remains to be 
explored whether NN has a differential effect in comparison 
with NRG on putative vascular and cardiac progenitor cells, 
which are reported to be specifically adversely affected by 
anthracycline exposure.33,34 Although the role of these cells 
in cardiac repair and regeneration is still unclear, a distinct 
effect of NN on them could potentially account for the differ-
ences observed in cardioprotection between NN and NRG in 
this study. In addition, it is possible that NN could stimulate 
cardiac regeneration via the division of preexisting cardio-
myocytes, as suggested for native NRG.28 A difference in the 
efficiency or efficacy of stimulation of regenerative pathways 
could lead to the differential protective effects observed in 
these studies. Finally, we cannot rule out a differential effect 
of NN in comparison with NRG owing to differences in 
the regulation of expression of topoisomerase-IIβ, which 
was recently identified as an essential mediator of DOXO-
induced cardiotoxicity.35 Further exploration of differential 
gene expression associated with NN and NRG may yield 
data to support or refute the potential association of NN and 
NRG with topoisomerase-IIβ expression.
In general, these data are congruent with previous work 
demonstrating the cardioprotective potential of NRG. Both 
the phosphoinositide-3 kinase/Akt and mitogen-activated 
protein kinase/ERK1/2 signaling pathways have previously 
been identified as critical mediators of NRG effects on 
cardiomyocytes that are not completely dependent on ErbB2 
participation in signaling.27 Thus, the ability of NN to activate 
these pathways (Figure 3), despite inducing relatively 
Figure 6. Bivalent neuregulin-1β (NN) confers functional protection from doxorubicin (DOXO) toxicity in vivo. A, Acute cardiomyopathy 
was induced with a single 20-mg/kg IP injection of DOXO. Mice were treated for 7 days with Vehicle (0.2% BSA in PBS), neuregulin-
1β (NRG), or NN at 100 μg/kg IP per day, with 3 injections occurring before DOXO administration. Mice given the same NRG or NN 
treatments without DOXO injection were used as controls and are shown to the right of the vertical dashed line. Fractional shortening 
(FS) as assessed by blinded echocardiography at 7 days is shown. The horizontal dotted line indicates the average FS of all animals at 
baseline echocardiography performed 2 days before the initial injection. Probability values were determined by using a Wilcoxon rank-
sum test with a Bonferroni correction (α=0.0125) after an initial Kruskal-Wallis test to determine statistical significance; no probability 
values in A meet the criteria for statistical significance. B, Immunoblot analysis of γ-H2A.X in cross-sectional heart lysates of study 
animals. GAPDH expression was assessed as a protein-loading control. C, Chronic DOXO-induced cardiomyopathy was induced with 
weekly serial 4-mg/kg IP injections of DOXO as shown. Beginning on the day of the initial DOXO injection for each 4-week series, mice 
were injected daily for 7 days with the vehicle solution, 0.2% BSA in PBS (DOXO), NRG, or NN at 50 μg/kg IP per day. Mice that were not 
injected with DOXO (Vehicle) were used as controls. Fractional shortening (FS) as assessed by blinded echocardiography 2 weeks before 
the initial DOXO injection and 6, 12, 22, and 24 weeks after the initial DOXO injection, respectively, is shown. Only end point values (24 
weeks) were analyzed; probability values were determined by using a Wilcoxon rank-sum test with a Bonferroni correction (α=0.0125) 
after an initial Kruskal-Wallis test to determine statistical significance. For C, probability values <0.0125 are considered statistically 
significant. BSA indicates bovine serum albumin; and PBS, phosphate-buffered saline.
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less ErbB2 phosphorylation than NRG (Figure 2), is not 
surprising. It is important to note, however, that the approach 
to manipulating ErbB receptor interactions with bivalent NN 
described here is fundamentally different from conventional 
receptor blocking or deletion approaches. It is well known 
that complete exclusion of ErbB2 from cardiac signaling, via 
either conditional knockout preclinical studies36 or clinically 
via the ErbB2-targeted antibody trastuzumab,20 is deleterious, 
especially so in conjunction with anthracycline exposure. 
NN induced partial biasing of ErbB receptor interactions 
and activation, but substantial ErbB2 phosphorylation was 
still observed (Figure 2 and Figure II in the online-only Data 
Supplement), and so the negative effects associated with 
ErbB2 blockade are avoided.
Table.  Echocardiographic Parameters After Serial Doses of Doxorubicin in Mice
  Treatment Baseline 24 wk P (24 wk vs DOXO)
n Vehicle 8 7† —
DOXO 12 7 —
DOXO+NRG 12 10 —
DOXO+NN 12 9† —
Anterior wall thickness, mm Vehicle 1.12±0.07 1.15±0.03 0.249
DOXO 1.12±0.05 1.20±0.11 —
DOXO+NRG 1.12±0.04 1.17±0.05 0.922
DOXO+NN 1.13±0.02 1.17±0.12 0.817
Posterior wall thickness, mm Vehicle 0.91±0.08 0.99±0.02 0.141
DOXO 0.89±0.06 0.91±0.12 —
DOXO+NRG 0.89±0.06 0.96±0.12 0.353
DOXO+NN 0.92±0.06 1.01±0.06 0.054
End-systolic diameter, mm Vehicle 1.08±0.06 1.20±0.05 0.002*
DOXO 1.05±0.11 1.49±0.26 —
DOXO+NRG 1.10±0.05 1.44±0.74 0.536
DOXO+NN 1.06±0.06 1.24±0.13 0.029
End-diastolic diameter, mm Vehicle 2.76±0.32 2.86±0.20 0.11
DOXO 2.66±0.23 3.04±0.17 —
DOXO+NRG 2.78±0.16 2.83±0.07 0.07
DOXO+NN 2.72±0.14 2.93±0.25 0.247
Fractional shortening, % Vehicle 60.53±4.26 57.99±3.21 0.011*
DOXO 60.28±4.21 50.94±6.88 —
DOXO+NRG 60.41±2.45 49.37±9.91 0.813
DOXO+NN 60.74±2.24 57.69±1.74 0.004*
Left ventricular mass, g Vehicle 93.74±15.78 112.26±11.19 1
DOXO 88.27±11.03 114.30±15.57 —
DOXO+ NRG 94.10±10.44 104.99±14.94 0.23
DOXO+NN 93.32±8.01 114.44±17.78 0.867
Body weight, g Vehicle 20.30±0.75 31.98±4.53 0.0006*
DOXO 20.21±0.92 23.46±2.53 —
DOXO+NRG 21.00±1.03 23.97±2.84 0.807
DOXO+NN 21.74±0.77 23.88±2.14 0.955
Heart rate, bpm Vehicle 536±49 519±81 0.331
DOXO 515±70 561±54 —
DOXO+NRG 574±66 447±100 0.028
DOXO+NN 548±45 484±84 0.072
Data are mean±standard deviation. Vehicle = vehicle injections (0.2% BSA in PBS, no DOXO); DOXO = 4 mg/kg DOXO IP injections weekly during weeks 0 to 4 and 
16 to 20; DOXO+NRG = 4 mg/kg DOXO IP injections weekly during weeks 0 to 4 and 16 to 20 with concurrent daily 50 μg/kg IP injections of NRG during weeks 0 and 
16; and DOXO+NN = 4 mg/kg doxorubicin IP injections weekly during weeks 0 to 4 and 16 to 20 with concurrent daily 50 μg/kg IP injections of NN during weeks 0 and 
16. BSA indicates bovine serum albumin; DOXO, doxorubicin; IP, intraperitoneal; NN, an engineered bivalent neuregulin-1β; NRG, epidermal growth factor–like domain 
of neuregulin-1β; and PBS, phosphate-buffered saline.
*P<0.0125 was considered statistically significant after Wilcoxon rank-sum test with Bonferroni correction.
†One animal from the Vehicle group and 2 animals from the DOXO+NN group were euthanized during the first 8 weeks of the study because of wounds received 
from fighting.
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In summary, the data show that NN is protective from 
DOXO-induced cardiotoxicity in vitro in rat and human car-
diomyocytes and in vivo in a mouse model. Based on these 
results, NN may have therapeutic potential in other cardiac 
pathologies, including acute or chronic ischemic heart dis-
ease. Additional results from ongoing clinical trials with 
NRG and GGF2 will help clarify the translational potential 
of NN.
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CLINICAL PERSPECTIVE
Doxorubicin (DOXO) is an anthracycline chemotherapeutic that is effective against particular subsets of various cancers; 
for example, ErbB2-overexpressing breast cancer. However, the use of DOXO is limited by a dose-related cumulative car-
diotoxicity that can lead to congestive heart failure. The relationship between DOXO dose and cardiotoxicity is sufficiently 
well-defined such that oncologists now limit cumulative dosage, and thus DOXO-induced cardiomyopathy is rarely seen 
clinically. Yet this dose limitation of DOXO is deleterious for those patients for whom it is the best available therapy for their 
cancer. Therefore, we used protein engineering to exploit the cardioprotective effects of the ErbB receptor ligand neureuglin-
1β (the epidermal growth factor-like domain of neureuglin-1β), which is a known cardioprotective protein that also has 
proneoplastic characteristics. We hypothesized that by taking advantage of known differences in ErbB receptor biology in 
cancer cells and cardiomyocytes, we could develop a protein that had the cardioprotective qualities of the epidermal growth 
factor-like domain of neureuglin-1β without the proneoplastic effects. The present study demonstrates that an engineered 
bivalent neuregulin-1β induces cytostatic and antineoplastic responses in cancer cells that are stimulated toward malignant 
phenotypes by the epidermal growth factor-like domain of neureuglin-1β while retaining efficacy as a cardioprotective agent 
in a chronic-administration mouse model of DOXO-induced cardiotoxicity. Based on these results, we believe that an engi-
neered bivalent neuregulin-1β has translational potential as a novel cardioprotective therapeutic for patients with cancer who 
may need to receive DOXO beyond the current cumulative dose threshold.
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Protein Design and Purification – Coding DNA for NN was designed in silico 
(SerialCloner) and obtained as a whole gene product without codon bias. The protein 
was expressed as a maltose binding protein (MBP) fusion in E. coli strain Origami 
B(DE3)PlysS (EMD Biosciences). The protein sequence was inserted, using standard 
restriction enzyme digestion/ligation techniques, into a modified pMAL-c5x vector (New 
England Biolabs) containing a poly-histidine sequence inserted 3 base pairs to the C-
terminal side of the start codon. A cleavage site for tobacco etch virus protease (TEVp) 
was incorporated directly N-terminal of the initial NRG domain. Protein expression was 
induced with 0.3mM IPTG for 4-24h and soluble protein was harvested following cell 
lysis with BugBuster MasterMix (Novagen) supplemented with PMSF and protease 
inhibitor cocktail (Sigma). Lysates were clarified by centrifugation at 4000 x g for 30min 
and the pellet discarded. Protein within the supernatant was purified on NiNTA resin 
(Invitrogen) according to the manufacturer’s protocol and then buffer exchanged into a 
redox refolding buffer (20mM Tris, 2mM GSH, 1mM GSSG, pH 8.5; all reagents from 
Sigma) via size exclusion high-performance liquid chromatography (HPLC). The purified 
fusion protein was then subjected to cleavage by TEVp for ~12h at 4°C. Cleaved protein 
was further purified by removal of MBP via amylose affinity chromatography (New 
England Biolabs) and isolation of non-aggregated protein by size exclusion HPLC, 
followed by an endotoxin removal step using an EndoTrap Red column (Profos). 
Bioactivity of purified protein was assessed using an MCF-7 proliferation assay
1.  
 
Cell culture – Human mammary adenocarcinoma cell line SK-BR-3 and human 
mammary ductal carcinoma cell line MDA-MB-175VII were cultured at 37°C with 5%  
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CO2 in DMEM + 10% fetal bovine serum (FBS, Aleken Biologicals). Both cell lines were 
purchased from the American Type Culture Collection.  
 
Neonatal rat cardiomyocytes were isolated as follows. Ventricles of 1- to 2-day old 
Sprague Dawley rats (Charles River Laboratories) were excised and minced, followed 
by serial digestion in an enzyme solution of pancreatin (0.06mg/ml, Sigma-Aldrich) and 
collagenase type II (0.04mg/ml, Worthington) in 1X HBSS (-) (Invitrogen) with 7.5% 
sodium bicarbonate (0.18%, Invitrogen). Cells were washed and pre-plated into T-75 
flasks in Dulbecco’s modified Eagle’s medium (DMEM) with low glucose (Invitrogen) 
containing 15% FBS, 1% penicillin/streptomycin supplement (Invitrogen), and 2.56% 1M 
HEPES (Invitrogen) to remove non-myocytes. After 2h, myocytes were plated at 
2.5x10
5 cells per 3.8 cm
2 well for eventual immunoblot analysis, at 2x10
6 cells per 9.6 
cm
2 for eventual proteomic array analysis, and at 50,000 cells per 0.3 cm
2 well for 
functional studies. After 18h, the medium was changed to serum-free DMEM (low 
glucose) and incubated for another 18h prior to stimulation. All cultures were kept at 
37°C, 95% humidity, and 5% CO2.  
 
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) were obtained 
from Cellular Dynamics International (iCell
 Cardiomyocytes) and were cultured 
according to the supplier’s instructions.  
 
Immunoblot Analysis – Cells or tissue samples were lysed in Bio-Plex Cell Lysis Buffer 
with the protease and phosphatase inhibitor cocktails Bio-Plex Factor 1 and Bio-Plex 
Factor 2 (Bio-Rad). Proteins were quantified using the MicroBCA Protein Assay Kit  
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(Pierce). Loading buffer and 0.5M 2-mercaptoethanol (Sigma-Aldrich) were added to 
protein samples, which were boiled for 5min and run on 4-12% Bis-Tris gels. 
Membranes were probed with primary antibodies (2241 pErbB2, 4791 pErbB3, 4060 
pAkt, 4370 pERK1/2, 2577 γ-H2A.X, 2118 GAPDH; all from Cell Signaling 
Technologies) and HRP-conjugated secondary antibodies (Bio-Rad).    
 
Proteomic Array Analysis – Phospho-Receptor Tyrosine Kinase (RTK) Array kits and 
Phospho-Kinase Array kits (R&D Systems) were used to determine relative levels of 
tyrosine phosphorylation of RTKs or intracellular kinases, respectively, in NRCM. 
Lysates and membranes were prepared according to the specifications of the product 
inserts.  
 
In Vitro Functional Assays – For cell viability studies with NRCM, cells were seeded at 
50,000 cells per well in 96-well plate for 36h in complete media. Medium was changed 
to serum-free medium containing the designated doses of DOXO and/or NRG or NN, 
and the cells were incubated for an additional 24h. Cell viability was assessed using 
CyQUANT-NF proliferation kit (Invitrogen). For cell viability studies with MDA-MB-
175VII, SK-BR-3, and HeLa, cells were seeded at 3,500/well in 96 well plates. For cell 
viability studies with iPSC-CM, cells were seeded into 12-well plates at 290,000 viable 
cells/well based on the supplier’s protocol. For apoptosis studies, NRCM were seeded 
at 50,000 cells/well in a 96 well plate. 24h later, medium was aspirated and replaced by 
new medium with and without NRG or NN in the presence of 1µM DOXO and incubated 
for an additional 24h. Caspase 3/7 activation was detected using the SensoLyte® 
Homogeneous AFC Caspase 3/7 Assay Kit (Anaspec).   
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Statistical Analysis – Data in Figure 1D were analyzed by a Wilcoxon rank-sum test. 
Data in Figures 3-6 and in Table 1 were initially analyzed by a Kruskal-Wallis test with 
Dunn’s multiple comparison post-tests to determine statistical significance and P values 
were then determined using a Wilcoxon rank-sum test with an appropriate Bonferroni 
correction.  For Table 1 and Figure 6, only endpoint data were analyzed and thus no 




















SUPPLEMENTAL FIGURES AND LEGENDS 
Supplemental Figure I 
 
 
Supplemental Figure I: Histological analysis of animals from chronic doxorubicin 
(DOXO) toxicity in vivo study. Chronic DOXO-induced cardiomyopathy was induced 
with weekly serial 4mg/kg intraperitoneal (ip) injections of DOXO as shown in Figure 7. 
Beginning on the day of the initial DOXO injection for each 4 week series, mice were 
injected daily for 7 days with the vehicle solution, 0.2% BSA in PBS (DOXO), 
neuregulin-1β (NRG), or bivalent NRG (NN) at 50µg/kg ip per day. Mice that were not 
injected with DOXO (Vehicle) were used as controls. Representative hematoxylin and 
eosin (H&E) stained slides revealed pockets of tissue that appeared necrotic (arrows), 
and these were most prevalent in the DOXO group. Representative Masson’s trichrome 
(Trichrome) stained slides revealed tissue that appeared fibrotic (arrows) in all DOXO-












Supplemental Figure II: Bivalent neuregulin-1β (NN) induces ErbB receptor 
phosphorylation in vivo. 8-12 week old female C57Bl/6 mice were intraperitoneally 
injected with 2.5µg/animal of neuregulin-1β (NRG) or NN and hearts were excised and 
homogenized at the indicated times post injection. Immunoblot analysis of ErbB 
receptor phosphorylation was carried out by standard methods and expression levels 
were quantified by densitometry using ImageJ software and normalized to GAPDH 
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